Open AccessThe anti‐angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts
Author(s) -
Rychli Kathrin,
Kaun Christoph,
Hohensinner Philipp J.,
Dorfner Adrian J.,
Pfaffenberger Stefan,
Niessner Alexander,
Bauer Michael,
Dietl Wolfgang,
Podesser Bruno K.,
Maurer Gerald,
Huber Kurt,
Wojta Johann
Publication year - 2010
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2009.00731.x
Subject(s) - myocyte , microbiology and biotechnology , pedf , medicine , human heart , biology , chemistry , endocrinology , cardiology , angiogenesis
Cardiac diseases such as myocardial infarction and heart failure are among the leading causes of death in western societies. Therapeutic angiogenesis has been suggested as a concept to combat these diseases. The biology of angiogenic factors expressed in the heart such as vascular endothelial growth factor (VEGF) is well studied, whereas data on anti‐angiogenic mediators in the heart are scarce. Here we study the expression of the anti‐angiogenic factor pigment epithelium‐derived factor (PEDF) in the human heart and in human cardiac cells. PEDF expression could be detected in human cardiac tissue on the protein and mRNA levels. PEDF mRNA levels were significantly lower in explanted human ischemic hearts as compared to healthy hearts. Our in vitro experiments showed that human adult cardiac myocytes and fibroblasts constitutively secrete PEDF. In addition to anoxic conditions, cobalt chloride, 2,2′dipyridyl and dimethoxally glycine, which stabilize hypoxia inducible factor‐α decreased PEDF expression. Furthermore we show that PEDF inhibits VEGF‐induced sprouting. We have identified PEDF in healthy and ischemic human hearts and we show that PEDF expression is down‐regulated by low oxygen levels. Therefore, we suggest a role for PEDF in the regulation of angiogenesis in the heart and propose PEDF as a possible therapeutic target in heart disease.